Sigma-1 Receptor-Mediated UPR Reset as Primary Disease-Modifying Mechanism of Trazodone at Low Doses
🧪 Overview
Trazodone acts as a sigma-1 receptor agonist at doses of 50-100 mg/day, promoting chaperone protein expression in the endoplasmic reticulum and resetting the PERK/eIF2alpha pathway from pro-apoptotic to pro-survival signaling. This UPR reset reduces chronic ER stress—a pathological hallmark shared by Alzheimer's disease and frontotemporal dementia—ultimately decreasing neuronal loss. However, trazodone's sigma-1 affinity (Ki ~300-500 nM) is weak, and the margin between therapeutic free brain concentrations and receptor Ki is uncomfortably narrow. Prior failure of more potent sigma-1 agonist SA-4503 in clinical trials for stroke and depression raises significant translational concerns.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["SIGMAR1<br/>Sigma-1 Receptor"]
B["BiP/GRP78<br/>Chaperone Dissociation"]
C["PERK/eIF2alpha<br/>UPR Activation"]
D["Unfolded Protein<br/>Response Reset"]
E["ER Stress<br/>Resolution"]
F["Synaptic<br/>Proteostasis"]
G["Neuroprotection<br/>Amyotrophic Disease"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SIGMAR1
No curated PDB or AlphaFold mapping for SIGMAR1 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for SIGMAR1, PERK/eIF2alpha axis, BiP/GRP78 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SIGMAR1, PERK.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF low-dose trazodone (50-100 mg/day for 12 weeks) is administered to early-stage Alzheimer's disease or frontotemporal dementia patients with elevated CSF XBP1 splicing (biomarker of chronic ER stres | CSF BiP/GRP78 levels increase ≥30% in trazodone arm vs. placebo | — no observation — | pending | 0.45 |
| IF human iPSC-derived cortical neurons undergoing chronic tunicamycin-induced ER stress are treated with trazodone (100-300 nM) co-administered with the selective sigma-1 antagonist NE-100 (100 nM), T | Phospho-PERK/PERK ratio remains elevated and CHOP is not suppressed in trazodone + NE-100 condition | — no observation — | pending | 0.60 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |